Efficacy and safety of flecainide in catecholaminergic polymorphic ventricular tachycardia

被引：0
|
作者：
Wanguemert Perez, F. [1 ]
Ruiz Hernandez, P. [2 ]
Berne, P. [3 ]
Campuzano Larrea, O. [4 ]
Bosch Calero, C. [4 ]
Perez, G. J. [4 ]
Perez Rodriguez, C. [1 ]
Brugada, J. [3 ]
Brugada, R. [4 ]
机构：
[1] Cardiavant, Las Palmas Gran Canaria, Spain
[2] Insular Hosp, Las Palmas Gran Canaria, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
[4] Univ Girona, Cardiovasc Genet Ctr, Girona, Spain
来源：
EUROPEAN HEART JOURNAL | 2013年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：831 / 831
页数：1
相关论文
共 50 条
  • [1] Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia
    Biernacka, Elzbieta Katarzyna
    Hoffman, Piotr
    EUROPACE, 2011, 13 (01): : 129 - 130
  • [2] The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia
    Lieve, Krystien V. V.
    Wilde, Arthur A.
    van der Werf, Christian
    ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW, 2016, 5 (01) : 45 - 49
  • [3] The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia
    Li, Yukun
    Peng, Xiaodong
    Lin, Rong
    Wang, Xuesi
    Liu, Xinmeng
    Bai, Rong
    Ma, Changsheng
    Tang, Ribo
    Ruan, Yanfei
    Liu, Nian
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [4] Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia A Randomized Clinical Trial
    Kannankeril, Prince J.
    Moore, Jeremy P.
    Cerrone, Marina
    Priori, Silvia G.
    Kertesz, Naomi J.
    Ro, Pamela S.
    Batra, Anjan S.
    Kaufman, Elizabeth S.
    Fairbrother, David L.
    Saarel, Elizabeth V.
    Etheridge, Susan P.
    Kanter, Ronald J.
    Carboni, Michael P.
    Dzurik, Matthew V.
    Fountain, Darlene
    Chen, Heidi
    Ely, Wesley
    Roden, Dan M.
    Knollmann, Bjorn C.
    JAMA CARDIOLOGY, 2017, 2 (07) : 759 - 766
  • [5] Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia A systematic review and meta-analysis
    Wang, Guangqiang
    Zhao, Na
    Zhong, Shu
    Wang, Yingrong
    Li, Jianping
    MEDICINE, 2019, 98 (34)
  • [6] Efficacy and safety of the ICD in patients with catecholaminergic polymorphic ventricular tachycardia
    Mazzanti, A.
    Trancuccio, A.
    Kukavica, D.
    Marino, M.
    Giannini, G.
    Rossetti, L.
    Memmi, M.
    Bloise, R.
    Morini, M.
    Napolitano, C.
    Priori, S. G.
    EUROPEAN HEART JOURNAL, 2022, 43 : 699 - 699
  • [7] Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans
    Watanabe, Hiroshi
    Chopra, Nagesh
    Laver, Derek
    Hwang, Hyun Seok
    Davies, Sean S.
    Roach, Daniel E.
    Duff, Henry J.
    Roden, Dan M.
    Wilde, Arthur A. M.
    Knollmann, Bjoern C.
    NATURE MEDICINE, 2009, 15 (04) : 380 - 383
  • [8] Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations
    Napolitano, Carlo
    HEART RHYTHM, 2016, 13 (02) : 614 - 615
  • [9] Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans
    Hiroshi Watanabe
    Nagesh Chopra
    Derek Laver
    Hyun Seok Hwang
    Sean S Davies
    Daniel E Roach
    Henry J Duff
    Dan M Roden
    Arthur A M Wilde
    Björn C Knollmann
    Nature Medicine, 2009, 15 : 380 - 383
  • [10] Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia
    Steele, Derek S.
    Hwang, Hyun-Seok
    Knollmann, Bjoern C.
    CARDIOVASCULAR RESEARCH, 2013, 98 (02) : 326 - 327
12345